Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 35.61 USD 2.24% Market Closed
Market Cap: 10.2B USD
Have any thoughts about
Exelixis Inc?
Write Note

P/E
Price to Earnings

21.8
Current
31.1
Median
22.7
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
21.8
=
Market Cap
10.1B USD
/
Net Income
466.9m USD
All Countries
Close
Market Cap P/E
US
Exelixis Inc
NASDAQ:EXEL
10.1B USD 21.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -180 080
US
Abbvie Inc
NYSE:ABBV
314.7B USD 61.9
US
Amgen Inc
NASDAQ:AMGN
157B USD 37.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD -241.6
US
Gilead Sciences Inc
NASDAQ:GILD
112.2B USD 890.3
US
Epizyme Inc
F:EPE
94.1B EUR -474.5
AU
CSL Ltd
ASX:CSL
133.6B AUD 32.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 17.8
US
Seagen Inc
F:SGT
39.3B EUR -54.9
NL
argenx SE
XBRU:ARGX
34.5B EUR -130.6
Earnings Growth
US
Exelixis Inc
NASDAQ:EXEL
Average P/E: 177
21.8
214%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.1
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
890.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
20.2
2-Years Forward
P/E
20.4
3-Years Forward
P/E
15.5

See Also

Discover More